When art therapy went chemical: Alfred Bader, pharmacology, and art brut, c.1950-1970s

Summary

Psychopharmacology profoundly reshaped psychiatry's view of art. Unearthing the historical context of art therapy, its origins are repositioned through evolving clinical practices and mind-altering drugs. Early 20th-century use of psychotropic drugs influenced the psychopathology of art. Later, psychiatrist Alfred Bader and pharmacologist Roland Fischer conducted post-WWII experiments involving psilocybin, highlighting consciousness in mental health discussions. Psychotherapists in psychology increasingly linked art brut and modernist aesthetics to neurobiology, defining madness as a social disease, impacting art and mental health.

Abstract

Abstract This article analyzes how psychopharmacology transformed the relationship between art and psychiatry. It outlines a novel genealogy of art therapy, repositioning its origins in the context of evolving clinical practices and discourses on mind-altering drugs. Evaluating the use of psychotropic drugs in connection with psychopathology of art in the first half of the twentieth century, the article then focuses on two post-Second World War experiments involving psilocybin conducted by psychiatrist Alfred Bader and pharmacologist Roland Fischer. Illustrating how consciousness was foregrounded in discussions about mental health and illness, the examples showcase how psychotherapists increasingly sought to articulate art brut and modernist aesthetics in a neurobiological fashion to define madness as a social disease.

Tags